

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

**UPDATE ON DIRECTOR'S INFORMATION PURSUANT TO RULE 17.50(2)(L)
AND RULE 17.50B OF THE GEM LISTING RULES**

This announcement is made by Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.50(2)(l) and rule 17.50B of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Chui Kwong Kau (“**Mr. Chui**”), an executive director of the Company, was a non-executive director of Hsin Chong Group Holdings Limited (“**HCGH**”) between the period from 23 May 2015 until his resignation on 29 March 2019. HCGH was a company incorporated in Bermuda, and together with its subsidiaries were principally engaged in building construction, civil engineering, electrical and mechanical installation, property development and investment. The securities of HCGH had been listed on the Main Board of the Stock Exchange until 31 December 2019. Mr. Chui was informed earlier this month that by an order dated 20 January 2020 made by the Supreme Court of Bermuda, HCGH was wound up upon the petition by a creditor of HCGH. Mr. Chui confirmed that he is not a party of such winding up proceedings and is not aware of any actual or potential claim that has been or will be made against him as a result of the above.

Mr. Chui confirms that save for those disclosed above, insofar as Rule 17.50(2)(l) of the GEM Listing Rules is concerned, there is no other matter which needs to be brought to the attention of shareholders of the Company.

For and on behalf of the Board
Hong Kong Life Sciences and Technologies Group Limited
Lu Zhiqiang
Executive Director and Chief Executive Officer

Hong Kong, 24 March 2020

As at the date of this announcement, the Board comprises (i) six executive Directors, namely Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Zhang James Jian Yuan, Dr. Sun Yu, Mrs. Cheung Fan Karen and Mr. Lau Ngai Cheung; and (ii) three independent nonexecutive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing and Mr. Tang Hua.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company’s website at <http://www.hklifesciences.com>.